FDA approves Pfizer’s biosimilar, ABRILADA (adalimumab-afzb) for multiple inflammatory conditions

This article was originally published here

“Biosimilars like ABRILADA represent an opportunity to help improve access to important treatment options for patients living with chronic, and often debilitating, inflammatory conditions,” said Richard Blackburn, Global

The post FDA approves Pfizer’s biosimilar, ABRILADA (adalimumab-afzb) for multiple inflammatory conditions appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply